Ansun Biopharma, Inc., announced that the first patient has been enrolled in its Phase III clinical trial evaluating the efficacy and safety of DAS181 for the treatment of hospitalized, immunocompromised patients with lower respiratory parainfluenza virus infection. The Phase 3 clinical trial, called STOP PIV, is being conducted in multiple study centers throughout the world.
Parainfluenza infection in normal, healthy patients is not life threatening. However, in a hospital setting, immunocompromised patients who are trying to recover form cancer or an organ transplant, can face grave respiratory complications that could be deadly or cause permanent lung damage.
A recombinant sialidase protein that can cleave sialic acid, the virus receptors located on the surface of epithelial cells lining the human respiratory tract. Treatment with DAS181 can block virus entry into respiratory epithelial cells, thus preventing viral infection and spreading. DAS181 is a host-directed therapy that has demonstrated anti-viral activity against sialic-acid dependent viruses such as parainfluenza, metapneumovirus, enterovirus 68 and influenza, including strains of influenza that have developed resistance to other drugs and pandemic strains, such as H7N9, H5N1, and H1N1 and others.
The Phase III clinical trial is a randomized, placebo-controlled, multicenter study to examine the efficacy and safety of DAS181 for the treatment of lower respiratory tract parainfluenza infection in immunocompromised patients. It is being conducted in centers throughout the US as well as Europe and Asia. The study is planned through December 2021.
Ansun Biopharma, Inc is a California-based biopharma focused on the development of unique host-directed anti-viral treatments. They have raised over $100 million since their founding.Source: Yahoo Finance